Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-7d is a highly selective, small molecule allosteric inhibitor of **phosphodiesterase-5 (PDE5)**, derived from the natural product evodiamine (EVO). Unlike traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil, which bind to the orthosteric active site, S-7d and its analogs target a unique allosteric pocket. Binding to this pocket induces a dramatic conformational change in the H-loop of the PDE5 enzyme (with movements up to 24 Å), which sterically blocks the binding of substrates or other inhibitors to the active site. This novel mechanism allows S-7d to achieve exceptional selectivity (>570-fold) over related isoforms such as PDE6C and PDE11A, potentially minimizing side effects like visual disturbances or muscle pain associated with off-target inhibition. Preclinical studies have demonstrated that S-7d is effective in treating pulmonary hypertension in vivo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-7d.